Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03903822 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 292
- Enrollment target
NCT03903822 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 292 participants.
The verdict
NCT03903822, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 292 participants
- Enrollment target
Study Summary
This study is being conducted to provide data on efficacy, safety, tolerability and PK of multiple topical formulation concentrations of PF-06700841 topical cream in the treatment of mild to moderate atopic dermatitis (AD). The study is intended to enable selection of the dose and dosing regimen (once daily \[QD\] vs twice daily \[BID\] application) for the future clinical development of topical PF-06700841.
Interventions
- DRUG Vehicle (Placebo)
- DRUG PF-06700841
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2019-05-13 |
| Est. Completion | 2020-05-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03903822
The ClinicalTrials.gov registry entry for NCT03903822 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle (Placebo) is the first listed.
NCT03903822 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03903822 about?
NCT03903822 is a clinical study titled "Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis". This study is being conducted to provide data on efficacy, safety, tolerability and PK of multiple topical formulation concentrations of PF-06700841 topical cream in the treatment of mild to moderate atopic dermatitis (AD). The study is intended to enable selection of the dose and dosing regimen (on...
What is the current status of trial NCT03903822?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 292 participants. The study started on 2019-05-13. Estimated completion is 2020-05-07.
What interventions are being tested in trial NCT03903822?
The interventions under investigation include: Vehicle (Placebo) (DRUG), PF-06700841 (DRUG).
Who is sponsoring clinical trial NCT03903822?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.